Fero-Gradumet

Quick links

Choose a section

Quick links to important sections

Advertisements

Fero-Gradumet

Advertisements
Advertisements

Method of action: Antianemic, Hematopoietic

Advertisements

Overview of Fero-Gradumet

Fero-Gradumet Quick Facts

Property Description
Active ingredient Ferrous Sulfate
Form Controlled-release oral tablet
Pharmacological class Antianemic agent / Mineral supplement
Common use Treating and preventing iron deficiency
Origin Synthetic inorganic compound

Fero-Gradumet: Definition and Pharmaceutical Classification

Fero-Gradumet is a therapeutic preparation designated as an oral preparation taken in the dosage form of a tablet. It is classified as an antianemic agent and hematopoietic agent due to its role in blood health, and is further categorized as a mineral supplement because its purpose is to provide an essential mineral to the body. The medication is characterized by its sustained-release formulation, a distinctive feature that utilizes the Gradumet proprietary delivery system to control the liberation of its core component over time. This design is clinically recognized to potentially reduce common gastrointestinal irritation compared to immediate-release iron salts.

Composition and Origin of the Active Ingredient

The active ingredient in this single-ingredient product is Ferrous Sulfate, an Iron salt supplying the body with Elemental iron. Ferrous Sulfate is a synthetic inorganic compound that is the most widely utilized form of oral iron replacement therapy globally. This establishes Ferrous Sulfate's position as a foundational element in iron correction therapy. While alternative Iron salts such as Ferrous fumarate and Ferrous gluconate exist, Fero-Gradumet specifically utilizes Ferrous Sulfate delivered in its unique format, Iron(II) Sulfate.

General Purpose: Why Fero-Gradumet Is Used

The general purpose of this supplement is the treatment of iron deficiency and the prevention of iron deficiency in individuals with documented needs. A typical, neutral use scenario involves supplementing iron levels in individuals whose dietary intake is insufficient or whose physiological demands are high. Its action is intended to support the body’s ability to restore depleted iron stores to healthy levels. By providing the essential Iron building block, the preparation helps patients with documented iron deficiency maintain fundamental cellular processes, addressing the primary clinical need for a deficiency correction.

Regulatory References

  1. Ferrous salt entry in WHO Essential Medicines List (eEML)
Advertisements

What side effects are possible with Fero-Gradumet?

Possible Side Effects and Safety Information

The safety profile of Fero-Gradumet (Ferrous Sulfate sustained-release) is primarily characterized by dose-related gastrointestinal adverse reactions and specific regulatory warnings regarding the risk of overdose.

Adverse Reaction Classification

Adverse reactions are officially categorized by their frequency, based on regulatory standards. The most frequently reported effects primarily affect the Gastrointestinal Disorders system-organ class.

Frequency Classification Identified Adverse Reaction
Very Common Darkening or black stools (melanostool)
Common Nausea, vomiting, abdominal discomfort, constipation, diarrhea
Rare Gastrointestinal ulceration, necrosis, or stenosis; hypersensitivity reactions

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious adverse reactions and limitations on use. The most critical safety hazard is Accidental Iron Poisoning, which is potentially fatal, especially in young children. Serious local tissue damage, such as Gastrointestinal Ulceration, has been documented, particularly associated with the sustained-release tablet retention.

Safety is formally restricted by Contraindications against use in certain conditions. The medication must not be used in individuals with non-iron deficiency anemias (e.g., hemolytic anemia) or known iron overload conditions like hemochromatosis. Regulatory documents also note that gastrointestinal effects may be more pronounced at the start of treatment and may diminish with continued use.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Fero-Gradumet

Warning: Accidental overdose of iron-containing products, like Fero-Gradumet, is a leading cause of fatal poisoning in children under six years of age.


Documented Overdose Presentations

Acute iron overdose initially affects the gastrointestinal system, and if severe, can progress to systemic toxicity.

Early Symptoms (Acute Phase) Severe Manifestations (Later Phase)
Vomiting, severe stomach pain, diarrhea Circulatory collapse (shock)
Bloody or tarry stools, weakness, drowsiness Seizures and coma

Required Emergency Action

If an accidental overdose is suspected, call a doctor or poison control center immediately. This required instruction is emphasized across regulatory documents due to the speed and severity of iron toxicity. Even if symptoms appear mild or temporary, the potential for a severe, delayed reaction is significant.

Special Considerations

The prolonged-release formulation (e.g., Fero-Gradumet) carries a specific risk of tissue necrosis if the tablet is accidentally aspirated (inhaled), requiring urgent medical attention. Treatment for confirmed severe iron toxicity often involves the use of the specific antidote, Deferoxamine, and hospital monitoring, including assessment of vital signs and iron levels.

Advertisements

Therapeutic Uses of Fero-Gradumet

What Fero-Gradumet Treats: Main Uses and Benefits

The therapeutic application of Fero-Gradumet is centered on addressing iron imbalance and is used to address the symptoms related to systemic imbalance. The medication is used to treat and prevent iron deficiency anemia and is relevant for managing symptoms related to systemic iron depletion.


Fero-Gradumet is primarily used for the treatment and prevention of absolute iron deficiency and the resulting condition, iron deficiency anemia. It addresses symptom clusters related to systemic imbalance, including chronic fatigue, physical discomfort, and certain neurological or physical signs like headaches and restless legs syndrome. The core therapeutic benefit addresses the deficiency, contributing to improved comfort during symptomatic periods.

It provides support during periods of heightened physiological demand, such as pregnancy, or during chronic loss scenarios like heavy menstrual bleeding. In these cases, it assists in maintaining iron levels to help prevent symptomatic deficiency.


Quick Fact: Therapeutic Use

Fero-Gradumet is commonly used for conditions characterized by periods of heightened symptoms, specifically the treatment of iron deficiency anemia and the prevention of iron deficiency in individuals with documented needs. The medication addresses symptom clusters that interfere with daily functioning, offering supportive relief when symptoms become more noticeable.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Fero-Gradumet? — Official Regulatory Information

Fero-Gradumet (Ferrous Sulphate) is restricted to use by patients with a confirmed iron deficient state.

Contraindicated (Must Not Use)

Use of Fero-Gradumet is formally contraindicated in the following groups:

  • Patients with known hypersensitivity or allergy to the active substance (Ferrous Sulphate) or any of the product's ingredients.
  • Patients who are already taking other medicines containing iron.
  • Individuals with conditions of iron overload, such as haemochromatosis or haemosiderosis.
  • Patients diagnosed with anaemias not caused by iron deficiency (e.g., hemolytic anemia).
  • Those with certain active severe gastrointestinal diseases, including active peptic ulcer, regional enteritis, and ulcerative colitis.

Restricted or Special Consideration

Age: The medicine is not recommended for children and adolescents under 12 years of age.

Pregnancy/Lactation: Use is restricted during the first thirteen weeks of pregnancy. It can be used after the first thirteen weeks and during breast-feeding, if clinically indicated.

Condition-Specific: Caution and special consideration are required for patients with difficulties swallowing, a history of peptic ulcer, intestinal obstruction, or diverticular disease of the intestine.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Fero-Gradumet is formally defined by pharmacokinetic restrictions that alter the absorption of both the iron and co-administered substances in the digestive tract. This effect is classified as clinically significant, leading to mandated administration rules outlined in official regulatory documents.

Interaction Type Interacting Substances and Required Separation
Reduced Drug Exposure (by Iron) The plasma concentration of medicines like Tetracycline and Quinolone antibiotics, Levothyroxine, Bisphosphonates, Levodopa, and Penicillamine can be reduced. Co-administration requires a typical separation of at least two hours to minimize this absorption effect.
Reduced Iron Exposure (by Substance) The absorption of the iron tablet is reduced by Antacids and mineral supplements containing Calcium, Magnesium, Zinc, or Phosphorus. Dietary components such as Tea, Coffee, Milk, and Wholegrain cereals are also documented to reduce the effective absorption of the iron salt.
Prohibited Combinations The simultaneous use of parenteral iron preparations and other oral iron-containing supplements is officially prohibited by regulatory authorities.

This interaction structure is centered on necessary time separation protocols for pharmaceutical agents whose absorption is compromised by the iron salt. This mandatory restriction is intended to preserve the exposure and therapeutic integrity of the co-administered medication.

Advertisements

Mechanism of Action

Fero-Gradumet delivers Fe^2+ (ferrous iron) as the active chemical moiety. The prolonged-release formulation facilitates the gradual delivery of Fe^2+ primarily to the proximal small intestine, the site of maximal absorption, to increase the total amount of available iron. Upon release into the duodenal and jejunal lumen, the elemental iron, which exists predominantly in the divalent Fe^2+ state, is recognized and transported into enterocytes via the Divalent Metal Transporter 1 (DMT1), a proton-coupled ion channel on the apical brush border membrane. The Fe^2+ subsequently enters the intracellular labile iron pool (LIP).

Within the enterocyte, a fraction of the iron is stored, but the majority is exported across the basolateral membrane into the systemic circulation by the transmembrane protein Ferroportin (Fpn). The exported Fe^2+ is immediately oxidized to Fe^3+ by the ferroxidase Hephaestin before being sequestered by the plasma transport protein Transferrin (Tf). Systemic Fe^3+-Transferrin complex is then delivered to tissues, most notably the bone marrow, where it is endocytosed via the Transferrin Receptor (TfR) to support the downstream synthesis of heme and hemoglobin, increasing the functional circulating iron pool.

Advertisements

Dosage and Administration Information

How to Use Fero-Gradumet: Administration Guidelines

Fero-Gradumet is a prolonged-release oral tablet containing Ferrous Sulfate. Its usage is designed to ensure the proper release and absorption of the iron. This section outlines the guidelines for administration.


Administration Scope

Instruction Element Administration Details
Route of administration Oral (swallowed by mouth).
Standard Dosing One tablet daily (105 mg Elemental Iron equivalent for some prolonged-release products).
Timing in relation to meals Ideally taken before food for best absorption. May be taken with meals to minimize gastrointestinal discomfort.
Age-group rules Not recommended for children under 12 years; for adolescents (over 12), the dose is typically the same as for adults.

Essential Administration Requirements

To preserve the unique delivery system of the prolonged-release tablet, specific procedural conditions must be followed:

  • Do not chew, crush, or suck the tablet; it must be swallowed whole with a sufficient amount of water. Violating this instruction can compromise the controlled release mechanism.
  • The treatment duration is generally determined by the need to replenish the body’s iron stores and should usually not exceed six months (or three months after anemia has been corrected).
  • If a dose is missed, it should be taken when remembered, but do not take two doses at the same time to make up for the missed dose.
Advertisements

Recent Clinical Evidence

Fero-Gradumet: Recent Clinical Evidence


Evidence for use in Treating Iron Deficiency Anemia (IDA)

Research examining iron deficiency anemia (IDA) primarily involves rigorous Randomized Controlled Trials (RCTs) and Systematic Reviews for oral iron, focusing on populations with documented IDA. Studies explored changes in key biomarkers like Hemoglobin (Hb) concentration and Serum Ferritin levels over short-term follow-up periods. Findings describe patterns observed in these biomarkers. Trials specifically reported on the incidence of gastrointestinal side effects, noting these are common and influence patient adherence, and monitored tolerability patterns of controlled-release formulations.


Evidence for use in Preventing Iron Deficiency in High-Risk Groups

Evidence for preventing iron deficiency in high-demand groups, such as pregnant women, is derived from Systematic Reviews and large intervention trials. Research explored the maintenance of iron status biomarkers throughout the risk period and examined the relationship between iron status and outcomes in children, such as low birth weight. Studies reported on patterns of iron status maintenance. However, findings were sometimes mixed regarding adherence, as gastrointestinal symptoms can limit patient compliance.


Evidence for use in Treating Iron Deficiency without Anemia (ID)

The evidence base for treating isolated iron deficiency (ID) relies on smaller Randomized Controlled Trials and observational studies. Researchers explored the correction of Serum Ferritin levels in populations, primarily women of reproductive age, whose Hemoglobin was normal. Studies reported measurements of Serum Ferritin levels that were monitored to determine if they fell into the defined repletion range. However, research exploring relief of non-specific symptoms, such as fatigue, is limited, and findings were mixed.


Long-Term Studies and Follow-Up Duration

Clinical studies typically monitored responses over defined time intervals, usually ranging from eight to sixteen weeks. There is limited information for long-term outcomes regarding supplementation continuing beyond the six-month mark outside of situations involving chronic blood loss. Follow-up durations were limited in many trials.


Evidence in Special Populations

Research has explored the use of oral iron in key special populations, including pregnant women and infants and children, to address deficiency. Studies also monitored oral iron's response in patient groups with specific co-occurring health conditions, such as chronic kidney disease. Findings describe group patterns, and results apply only to the populations studied.


What is Still Uncertain About the Research

Research highlights areas of uncertainty. Data for the relief of general symptoms, such as fatigue not directly linked to IDA, are still emerging. Furthermore, studies exploring controlled-release formulations like Fero-Gradumet suggest that modified-release iron may be associated with uniformly lower absorption compared to immediate-release iron salts. Comparative evidence exploring whether this difference in absorption affects long-term treatment outcomes is still emerging.

Key Studies & References

  1. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial
  2. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women
Advertisements

How should Fero-Gradumet be stored and disposed of?

How to Store and Dispose of Fero-Gradumet

Fero-Gradumet must be stored according to official regulatory specifications to maintain its three-year shelf life and ensure safety. Storage conditions are defined by the need to protect the product and prevent accidental iron poisoning.


Storage Requirements

  • Temperature and Environment: The tablets must be stored at room temperature and at a maximum temperature below 30°C. They should be kept in a cool, dry place and protected from both moisture and direct sunlight.
  • Container: The medicine should remain in its original container, which must be kept tightly closed.
  • Child Safety: It is mandatory to store Fero-Gradumet out of the sight and reach of children due to the serious risk of fatal iron poisoning from accidental ingestion.

Official Disposal Rules

Expired or unused Fero-Gradumet must be managed as pharmaceutical waste. Official instructions state that the medicine should be discarded using a drug take-back program or authorized collection site. It is prohibited to dispose of the medicine by flushing it into wastewater (drains or toilets).

Advertisements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fero-Gradumet found in:

A-Z Index: